Kawasaki
Veille bibliographique : Maladie de Kawasaki
Les articles sont classés du plus ancien au plus récent, n’hésitez pas à utiliser la barre de recherche pour filtrer les résultats par date par exemple.
| Alphonse MP et al. Inositol-Triphosphate 3-Kinase C Médiates Inflammasome Activation and Treatment Response in Kawasaki Disease. J Immunol 25 nov 2016 | Lire le résumé |
| Manlhiot C, Mueller B, O’Shea S, Majeed H, Bernknopf B, Labelle M, et al. Environmental epidemiology of Kawasaki disease: Linking disease etiology, pathogenesis and global distribution. Kuo H-C, editor. PLOS ONE. 2018 Feb 7 | Lire le résumé |
| Chen KYH, Messina N, Germano S, Bonnici R, Freyne B, Cheung M, et al. Innate immune responses following Kawasaki disease and toxic shock syndrome. Proost P, editor. PLOS ONE. 2018 Feb 15. | Lire le résumé |
| Chbeir D, Gaschignard J, Bonnefoy R, Beyler C, Melki I, Faye A, et al. Kawasaki disease: abnormal initial echocardiogram is associated with resistance to IV Ig and development of coronary artery lesions. Pediatric Rheumatology [Internet]. 2018 Dec [cited 2018 Oct 24];16(1). | Lire le résumé |
| Li Y, Li Y, Zheng Q, Zou L, Wu J, Guo L, Teng L, et al. Kawasaki disease shock syndrome: clinical characteristics and possible use of IL-6, IL-10 and IFN-γ as biomarkers for early recognition. Pediatric Rheumatology [Internet]. 2019 Dec [cited 2019 Feb 7];17(1). Available from: https://ped-rheum.biomedcentral.com/articles/10.1186/s12969-018-0303-4 | Lire le résumé |
| Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. The Lancet. mars 2019;393(10176):1128‑37 | Lire le résumé |
| Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 23 juill 2020;383(4):334‑46 | Lire le résumé |
| Zandstra J, van de Geer A, Tanck MWT, van Stijn-Bringas Dimitriades D, Aarts CEM, Dietz SM, et al. Biomarkers for the Discrimination of Acute Kawasaki Disease From Infections in Childhood. Front Pediatr [Internet]. 22 juill 2020 [cité 27 août 2020];8 | Lire le résumé |
| Sharma C, Ganigara M, Galeotti C, Burns J, Berganza FM, Hayes DA, et al. Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison. Nat Rev Rheumatol. déc 2021;17(12):731‑48 | Lire le résumé |
| Burney JA, Roberts SC, DeHaan LL, Shimizu C, Bainto EV, Newburger JW, et al. Epidemiological and Clinical Features of Kawasaki Disease During the COVID-19 Pandemic in the United States. JAMA Netw Open. 17 juin 2022;5(6):e2217436 | Lire le résumé |
| Chen YC, Pan HG, Jia DS, Wang HC, Li L, Teng YS. Clinical features of Kawasaki disease initially mimicking retropharyngeal abscess: a retrospective analysis. Pediatr Rheumatol Online J. 2022 Dec | Lire le résumé |
| Wang H, Shimizu C, Bainto E, Hamilton S, Jackson HR, Estrada-Rivadeneyra D, et al. Subgroups of children with Kawasaki disease: a data-driven cluster analysis. Lancet Child Adolesc Health. oct 2023;7(10):697‑707. | Lire le résumé |
| Kuniyoshi Y, Tsujimoto Y, Banno M, Taito S, Ariie T, Takahashi N, et al. Prediction Models for Intravenous Immunoglobulin Resistance in Kawasaki Disease: A Meta-analysis. Pediatrics. 1 mai 2023;151(5):e2022059175 | Lire le résumé |
| Hayashi K, Miyakoshi C, Hoshino S, Kobayashi N, Nakajima R, Sagawa H, et al. Initial intravenous immunoglobulin therapy without aspirin for acute Kawasaki disease: a retrospective cohort study with a Bayesian inference. BMJ Paediatr Open. janv 2024;8(1):e002312 | Lire le résumé |